Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine

Lin, Jiang-Tao, Zhang, Jian-San, Su, Nan, Xu, Jian-Guo, Wang, Nan, Chen, Jiang-Ting, Chen, Xin, Liu, Yu-Xuan, Gao, Hong, Jia, Yu-Ping, Liu, Yan, Sun, Rui-Hua, Wang, Xu, Yu, Dong-Zheng, Hai, Rong, Gao, Qiang, Ning, Ye, Wang, Hong-Xia, Li, Ma-Chao, Kan, Biao, Dong, Guan-Mu, An, Qi, Wang, Ying-Qun, Han, Jun, Qin, Chuan, Yin, Wei-Dong, Dong, Xiao-Ping·2007·Antiviral Therapy

Abstract

Background: Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health. Methods: To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control. Results: On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later. Conclusion: The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/135965350701200702

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 167

Metadata

Authors
Lin, J.-T., Zhang, J.-S., Su, N., Xu, J.-G., Wang, N., Chen, J.-T., Chen, X., Liu, Y.-X., Gao, H., Jia, Y.-P., Liu, Y., Sun, R.-H., Wang, X., Yu, D.-Z., Hai, R., Gao, Q., Ning, Y., Wang, H.-X., Li, M.-C., Kan, B., Dong, G.-M., An, Q., Wang, Y.-Q., Han, J., Qin, C., Yin, W.-D., & Dong, X.-P.
Venue
Antiviral Therapy
Published
2007-10
Volume
12
Issue
7
Pages
1107-1114
ISSN
  • 1359-6535 (ISSN-L)
  • 2040-2058
OpenAlex
W2398175096
Cited by
167
References
1
FWCI
2.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine. https://app.cochat.ai/papers/10.1177/135965350701200702
The paper
Lin, J.-T., Zhang, J.-S., Su, N., Xu, J.-G., Wang, N., Chen, J.-T., Chen, X., Liu, Y.-X., Gao, H., Jia, Y.-P., Liu, Y., Sun, R.-H., Wang, X., Yu, D.-Z., Hai, R., Gao, Q., Ning, Y., Wang, H.-X., Li, M.-C., . . . Dong, X.-P. (2007). Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine. Antiviral Therapy. https://doi.org/10.1177/135965350701200702

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.